The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. In this study of 1006 men with CRPC, the median serum testosterone level was 14.5 ng per 100 ml (range 0-270), the median BMI was 27 kg m À2 (range 15.7-46.5), and 26% of men were obese or morbidly obese (BMIX30). Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity. In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines. Higher testosterone levels among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men.
Introduction
Approximately 75 men will die on a daily basis from advanced prostate cancer in the United States in 2008, underscoring the need for improved outcomes in this common illness. 1 Survival of men with castrationresistant metastatic prostate cancer (CRPC) can range from several months to several years. 2, 3 However, current prognostic models in CRPC only account for approximately 70% of the explained variability in survival outcomes and natural history of this disease, indicating that additional prognostic factors are likely implicated in prostate cancer outcomes. [3] [4] [5] There is a growing prevalence of obesity in the United States and worldwide. 6 Numerous studies have demonstrated adverse outcomes associated with elevated body mass index (BMI) and the presence of obesity in men with localized prostate cancer. [7] [8] [9] [10] [11] [12] Obesity is associated with higher Gleason sum, more advanced disease at diagnosis, a higher risk for prostate-specific antigen (PSA) recurrence after local therapy and higher mortality rates in men with prostate cancer. 7, 8, 11, 13 These effects may be mediated through differential screening patterns, false-negative biopsies due to large prostate volumes, hemodilution of PSA, biologic factors such as elevated insulin and insulin-like growth factor (IGF) levels, alterations in testosterone and estrogen levels and other factors. [13] [14] [15] [16] Docetaxel clearance may be increased in obese men, and may vary according to testosterone levels, thus potentially leading to heterogeneity in dose intensity and undertreatment. 17, 18 There is evidence that prostate cancer may remain androgen-receptor-dependent even in the castration-resistant state, [19] [20] [21] [22] but it remains unclear if obesity and/or testosterone levels in men with CRPC have prognostic significance. We therefore sought to investigate the prognostic significance of baseline BMI and serum testosterone levels in predicting outcomes for men with CRCP recruited to the international multicenter TAX327 study. 23 
Materials and methods
TAX327 was a randomized, nonblinded, multinational phase III study involving 1006 men with progressive metastatic CRPC. Full details of the eligibility and baseline characteristics are provided in the original report. 23 Briefly, men were eligible if they had documented metastatic prostatic adenocarcinoma in the face of castrate levels of serum testosterone (p50 ng ml À1 ), and had evidence of progression as defined by clinically or radiographically measurable disease or by PSA criteria. Baseline information collected on each individual included height, weight, testosterone levels, serum PSA, age, performance status, pain and analgesic score, hemoglobin, alkaline phosphatase, prior Gleason sum or tumor grade, presence of visceral metastases, location and number of metastases, prior therapies, and how progression was defined, in addition to other clinical and demographic variables. An approved and signed institutional review board informed consent form was obtained for all participants at each participating institution.
The primary end point of this analysis was duration of survival as defined by the time from randomization to death due to any cause, with the survival data updated as of 7 November 2006. Patients who were alive as of the cutoff date were censored on this date, and those who were lost to follow-up were censored at the time of last contact date or clinic visit. The Kaplan-Meier product limit estimator was used to estimate the survival distribution by National Institutes of Health -defined BMI categories. Univariate and multivariable proportional hazards modeling was performed using Stata 9.2 software (Statacorp LP, College Station, TX, USA). The proportional hazard assumptions were tested using Schoenfeld residual analysis for univariate and multivariable analysis with a level of significance of 0.01. Nonnormally distributed variables such as testosterone levels were logarithmically transformed or categorically evaluated using various thresholds. Comparisons of baseline characteristics by BMI groups (obese vs nonobese) were performed using 95% confidence intervals (CIs), t-tests and exploratory statistical analysis for linear trends across categorical variables. Covariates of interest for multivariable analysis are those recently published but include baseline performance status, pain, hemoglobin, alkaline phosphatase, PSA, presence of liver metastases, PSA-doubling time (PSADT), type of progression (measurable and bone scan), number of metastatic sites, tumor grade (Gleason and WHO combined) and treatment group. 3 Parameters (other than PSADT and BMI) were prospectively collected on case report forms. BMI was defined as weight in kilograms divided by the height in meters squared (kg m
À2
). Total serum testosterone was measured at baseline at each participating site (noncentralized analysis) and reported in ng per 100 ml.
Secondary outcomes of this analysis included the proportion of men with PSA declines (X30 and X50%) following chemotherapy initiation, with a PSA response being defined as a confirmed PSA decline by X50% from baseline among those with baseline PSAX20. A Po0.01 was used for significance of tested outcomes given the multiple comparisons performed in this analysis.
Results
A total of 1001 men were available for this analysis who provided adequate baseline information on serum levels of testosterone (n ¼ 1001) and had baseline height and weight recorded (n ¼ 1005). The characteristics of the analysis population according to baseline presence of obesity are shown in Table 1 . The median BMI in this study was 27.5 kg m À2 (range 15.7-46.5), and 24% were categorized as obese, defined as a BMIX30. Severe obesity (BMIX35) was present in 5.1%. Obese men were more likely to be younger (median 66 vs 69 years; P ¼ 0.0001), have marginally higher levels of testosterone (17 vs 14 ng per 100 ml; P ¼ 0.4) with a greater proportion BMI and testosterone in CRPC AJ Armstrong et al of obese men having a testosterone X30 ng per 100 ml (21 vs 15%; P ¼ 0.04). Obese men were more likely to have a lower PSA (mean 267 vs 508 ng ml À1 ) but these differences were not statistically significant (P ¼ 0.1). Obese men were significantly more likely than nonobese men to have a good performance status (P ¼ 0.02), fewer visceral metastases (P ¼ 0.01), higher grade disease (P ¼ 0.02) and higher hemoglobin (Po0.0001). The mean alkaline phosphatase level was significantly higher in nonobese men than obese men (median 212 vs 180 IU l À1 ; P ¼ 0.006). Likewise, across BMI categories (o25, 25-29.9, 30-34.9, 435 kg m À2 ), baseline alkaline phosphatase significantly decreased from 514 to 451 to 346 to 272, respectively (P trend ¼ 0.004). The distribution of obese men across the three treatment groups did not differ (P ¼ 0.68).
The median baseline testosterone level in this study was 14.5 ng per 100 ml (range 0-270) and had a truncated and skewed distribution (Figure 1 ). Baseline characteristics according to level of testosterone are shown in Table 2 . Men with low testosterone (less than the median) had similar baseline characteristics compared to men with a testosterone greater than the median. However, men with lower testosterone levels had a slower mean PSADT (90 vs 67 days; P ¼ 0.001). Mean baseline testosterone levels did not differ according to treatment groups (analysis of variance; P ¼ 0.48).
Prostate cancer-specific outcomes did not differ significantly by BMI class (o25, 25-30, 30-35 and 435 kg m
À2
; Table 3 ) in unadjusted or adjusted multivariable proportional hazards analyses, although overall survival (OS) was improved in univariate analysis for obese men as compared to nonobese men (19.1 vs 17.6 months; Table 1 ). The statistical significance of this finding was lost after adjusting for known baseline prognostic factors. 3 The proportion of men achieving a protocol-defined PSA response did not differ according to BMI categories, although a marginally higher proportion of obese and morbidly obese men had a X30% 3-month PSA decline after starting chemotherapy (P ¼ 0.02 for trend). The Kaplan-Meier estimates for OS (over 90% of deaths in this study were prostate cancer-specific events) stratified by the presence of obesity are shown in Figure 2a , and by BMI categories in Figure 2b . The hazard for death per unit increase in BMI was 1.01 (95% CI, 0.99-1.03; P ¼ 0.32). Thus, OS was not significantly different in multivariable analysis for obese as compared to nonobese men with CRPC.
Prostate cancer-specific outcomes also did not differ significantly according to baseline testosterone levels, whether set at the median (Table 4) or at arbitrary thresholds of 10 ng per 100 ml increments. Although the eligibility criteria specified that testosterone levels should be p50 ng per 100 ml, 22 subjects had a testosterone level 450 ng per 100 ml. These patients had a survival of 26.2 months, but this was not statistically different than those men with undetectable levels of testosterone (17.2 months, hazards ratio, HR, 0.71; P ¼ 0.19). There was no difference in OS according to testosterone thresholds within the castrate range (P trend ¼ 0.21), or when separated at 30 ng per 100 ml (HR 0.95; P ¼ 0.62), as shown in Figures 3a and b . In an additional exploratory analysis, men (n ¼ 77) who received further hormonal manipulations (that is, antiandrogens, ketoconazole) following progression on chemotherapy had a nonsignificantly prolonged survival if their baseline testosterone was greater than the median Testosterone Level (ng/dl) Figure 1 Histogram distribution of serum testosterone levels at baseline in the TAX327 study. 
Discussion
In this retrospective secondary analysis of a large international multicenter clinical trial of men with CRPC, we found no significant association between BMI, the presence of obesity, or baseline levels of testosterone with prostate cancer outcomes including survival or PSA declines. Obese men had fewer adverse prognostic factors, including fewer visceral metastases, lower PSA and alkaline phosphatase levels, better performance status, and higher hemoglobin levels; however, they had higher grade disease and similar PSA kinetics, measures of pain, and number of metastatic sites. These baseline differences likely confound the beneficial association that was seen in the unadjusted analysis of OS, and with appropriate adjustment for these prognostic factors, an independent relationship of obesity and survival was not observed. Although obese men had a slightly higher level of testosterone, confirming the findings of others, these differences were not clinically significant in this advanced castration-resistant population. 24 A higher level of testosterone in obese men may indicate inadequate testosterone suppression with current dosing regimens of GnRH agonists, and may be more important for androgen-sensitive disease. 24 However, the testosterone threshold for eligibility in clinical trials of men with CRPC should remain less than or equal to 50 ng per 100 ml, given that lower levels were not prognostic of OS.
The lower levels of PSA and alkaline phosphatase in obese men in this study suggest that these biomarkers may be subject to hemodilution. This has been recently described for PSA, and Halabi et al.
14,25 recently described a similarly lower level of alkaline phosphatase in obese men with CRPC. The 15-20% lower alkaline phosphatase and PSA levels in obese men may thus obscure the prognostic ability of these variables in this population and may have implications for other diseases in which alkaline phosphatase is used. [3] [4] [5] We found no evidence of differential outcomes related to obesity in men treated with current chemotherapy regimens for prostate cancer. One limitation to this study was the lack of data on weight change, either preceding enrolment or following treatment, which may have prognostic importance. 26 Men with cachexia from overwhelming tumor burden thus may not be captured in this analysis. Only 0.3% of men (4 of 1006) in this study were classified as underweight (BMI o18.5 kg m À2 ), and thus baseline weight would have to be analyzed in the context of weight change over the past years or other as the reference population in this study, which may have included some men who lost weight and fell into this category. A large proportion of men in this study, however, were obese (24%), and this did not adversely affect survival or prostate cancer outcomes. The higher proportionate decline in PSA across BMI categories following chemotherapy (X30% PSA decline from baseline within 3 months) is intriguing but likely due to chance, given that the rates of confirmed PSA declines X50% with therapy did not differ across BMI categories. These findings agree with those of Montgomery et al. 27 who conducted a similar analysis of BMI in men with CRPC and found no association with PSA declines or OS. 27 As a secondary exploratory outcome, OS was found to be nonsignificantly prolonged in men who received subsequent hormonal manipulations after chemotherapy among those men with relatively higher levels of testosterone compared to those men with lower levels. Although not statistically significant and possibly explained by chance alone, this finding suggests that there may be some level of androgen sensitivity following progression on chemotherapy. This finding has been suggested by others but is limited here by the lack of randomization to subsequent therapies, small sample size and the retrospective nature of this analysis. 19, 28 Further evaluation of agents targeting the androgen axis following chemotherapy should be studied in the context of controlled trials.
In conclusion, we did not find evidence for a differential impact of BMI or castrate-range testosterone levels on prostate cancer outcomes in this international phase III study of men with CRPC. Further studies of residual androgen-receptor activity in men with CRPC are warranted and may lead to improved prognostication and therapies. Finally, further studies evaluating weight loss over time may identify this factor as a more suitable prognostic factor for evaluation. BMI and testosterone in CRPC AJ Armstrong et al
